Skip to main content
. 2022 Nov 11;12:19275. doi: 10.1038/s41598-022-22078-3

Table 3.

Associations between self-reported MG severity and MGQOL15 scale scores (z-transformed continuous outcome).

M1:
self-reported severity
N=1053
M2: additionally adjusted
for depression
N=1049
M3: additionally adjusted
for gender
N= 1049
M4: additionally adjusted for other variablesa
N= 975
Self-reported MG severity
Moderate vs. mild 13.16 (11.63–14.69) 9.40 (8.07–10.72) 8.99 (7.68–10.30) 8.09 (6.75–9.44)
Severe vs. mild 18.26 (15.92–20.60) 15.37 (13.39–17.35) 15.09 (13.15–17.04) 14.36 (12.23–16.48)
Depression (HADS)
mild vs. healthy* 11.56 (9.85–13.27) 11.67 (9.98–13.35) 11.51 (9.78–13.23)
moderate vs. healthy 16.81 (14.79–18.83) 16.82 (14.83–18.81) 17.00 (15.01–19.00)
severe vs. healthy 21.37 (17.71–25.02) 21.69 (18.10–25.29) 21.05 (17.33–24.77)
gender
Female vs. male 3.54 (2.36–4.72) 2.86 (1.48–4.24)
Other autoimmune disorder 1.58 (0.11–3.05)
Rituximab or IVIG intake 3.83 (1.83–5.84)
thymectomy − 0.85 (− 2.23–0.51)
Adj R2 0,264 0,490 0,506 0,560

Stepwise Linear regression analysis. Estimated marginal means with 95%CI for MGQOL15 scale scores. *healthy = no depression according to HADS.

aM4: Additionally adjusted for thymectomy, other autoimmune disease, cardiovascular disease, IVIG/Rituximab, myasthenic crisis/exacerbation, duration, disease latency age, education, marital status.